Skip to main content

Fiscal Wizard · Single-issue tearsheet

EXEL / Jun 21, 2026 Run #7534

EXEL

Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Composite verdict

A 89.4 / 100
Bullish setup · Trend Following 11 drivers · 2 gates blocking
  • Stochastic RSI
  • Fibonacci Retracement
  • Vortex Signal
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 7th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 20 signals0% Bear
Momentum Bullish 95Mean-reversion Neutral 55
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
Where value comes fromMargin of safety -73%
Asset value $8.60Earnings power value $33.98Price $51.91

Priced above its no-growth earnings power value ($33.98/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Strong

78.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Margin of Safety 0
EPS Growth (YoY) 100
Inventory Turnover 0
Asset Turnover 100
Gross Margin 25

Technicals Bullish

100.0 / 100

Bullish setup leads (Stochastic RSI, Fibonacci Retracement, Vortex Signal); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 86
Stochastic RSI 84
Fibonacci Retracement 84

Risk Gates

2 blocking 7 caution

2 guards active, 22 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for EXEL.